AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33411824 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRe-p intervention (Adverse Drug Reaction Profile for polypharmacy)
Number of subjects: 19
Study 33411824 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRe-p intervention
Number of subjects: 19
Study 33411897 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg subcutaneously at least 1 week before the first cycle of chemotherapy and then every 4 weeks during chemotherapy)
Number of subjects: 149
Study 33411897 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 149
Study 33411897 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 149
Study 33411980 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Scale for the Elderly (PASE) scores of 101-140
Number of subjects: 2167
Study 33411980 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Scale for the Elderly (PASE) scores of >220
Number of subjects: 2167
Study 33411980 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Scale for the Elderly (PASE) scores of ≤100
Number of subjects: 2167
Study 33412162 — intervention group
Group type: EXPERIMENTAL
Intervention: MYO9A loss of function nonsense heterozygous mutation (p.Arg701)
Number of subjects: 0
Study 33413235 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9-mFIN
Number of subjects: 64
Study 33413284 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the bladder health instrument
Number of subjects: 1202
Study 33413284 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the bladder health instrument
Number of subjects: 1202
Study 33413284 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day voiding symptom diary
Number of subjects: 1202
Study 33413284 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day frequency volume diary
Number of subjects: 1202
Study 33413284 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized cough stress test
Number of subjects: 1202
Study 33413284 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive urine flowmetry
Number of subjects: 1202
Study 33413284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical urine analysis
Number of subjects: 1202
Study 33413284 — intervention group
Group type: EXPERIMENTAL
Intervention: Post void residual measurement
Number of subjects: 1202
Study 33413284 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent judge ratings of bladder health
Number of subjects: 1202
Study 33413357 — intervention group
Group type: EXPERIMENTAL
Intervention: NIATx200 intervention
Number of subjects: 908
Study 33413357 — intervention group
Group type: EXPERIMENTAL
Intervention: NIATx200 participation level
Number of subjects: 908
Study 33413366 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic-IR (DIR)
Number of subjects: 174
Study 33413366 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 174
Study 33413366 — intervention group
Group type: COMPARATOR
Intervention: Insulin Sensitive (IS)
Number of subjects: 174
Study 33413366 — intervention group
Group type: COMPARATOR
Intervention: Likely-IR (LIR)
Number of subjects: 174
Study 33413393 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of RO33 genetic variant
Number of subjects: 724
Study 33413393 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplicity of infection (MOI)
Number of subjects: 724
Study 33413393 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasite density
Number of subjects: 724
Study 33413393 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) level
Number of subjects: 724
Study 33413393 — intervention group
Group type: EXPERIMENTAL
Intervention: Other allelic families (K1, MAD20, FC27, 3D7)
Number of subjects: 724
Study 33413441 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over M1
Number of subjects: 0
Study 33413441 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS over PMAs
Number of subjects: 0
Study 33413492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 × 5 Gy
Number of subjects: 96
Study 33413492 — intervention group
Group type: COMPARATOR
Intervention: 10 × 3 Gy
Number of subjects: 96
Study 33413552 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 93
Study 33413552 — intervention group
Group type: COMPARATOR
Intervention: Before treatment (BT) group
Number of subjects: 93
Study 33413574 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex immunofluorescence (mIF)
Number of subjects: 25
Study 33413574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical linear modeling
Number of subjects: 25
Study 33413583 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion for 6 hours to decrease heart rate by 20%.
Number of subjects: 9
Study 33413583 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion for 6 hours.
Number of subjects: 9
Study 33413596 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive family history assessment of up to four generations
Number of subjects: 1750
Study 33413596 — intervention group
Group type: COMPARATOR
Intervention: Average family history cancer risk cohort
Number of subjects: 1750
Study 33413596 — intervention group
Group type: COMPARATOR
Intervention: Family history not available cohort
Number of subjects: 1750
Study 33413596 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of 25 cancer genes in ACMG Secondary Findings
Number of subjects: 1750
Study 33413596 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased family history cancer risk without actionable variant
Number of subjects: 1750
Study 33413658 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to an evidence-based patient information resource and the PExMS-website for 4 weeks
Number of subjects: 55
Study 33413658 — intervention group
Group type: COMPARATOR
Intervention: Access to evidence-based information alone (Control group)
Number of subjects: 55
Study 33413664 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair and usual post-operative rehabilitation
Number of subjects: 76
Study 33413664 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapist-led exercise
Number of subjects: 76
Study 33413677 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of endometriosis (excision or ablation)
Number of subjects: 90
Study 33413677 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic laparoscopy alone (with a sham port to achieve blinding)
Number of subjects: 90
Study 33413688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile technology supervision
Number of subjects: 0
Study 33413688 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-Centered Design (HCD) workshop
Number of subjects: 0
Study 33413809 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 467
Study 33413863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioband tricuspid system
Number of subjects: 30
Study 33414259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical interventions (PIs) by clinical pharmacist during the PICC process
Number of subjects: 277
Study 33414758 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (Acthar® Gel)
Number of subjects: 0
Study 33414828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg/d) tapered off by week 24
Number of subjects: 20
Study 33414927 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 20
Study 33415096 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33415114 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic burnout
Number of subjects: 0
Study 33415416 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib dihydrochloride (20, 30, and 60 mg daily)
Number of subjects: 226
Study 33415580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 5
Study 33415656 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) therapy for 1 month
Number of subjects: 46
Study 33415656 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) therapy for 6 months
Number of subjects: 46
Study 33415992 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33416257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization therapy (level + duration)
Number of subjects: 150
Study 33416257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization therapy (duration)
Number of subjects: 150
Study 33416257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization therapy (level)
Number of subjects: 150
Study 33416261 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with checkpoint inhibitors
Number of subjects: 0
Study 33416261 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study 33416261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological or molecular inhibition of autophagy
Number of subjects: 0
Study 33416261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer vaccines
Number of subjects: 0
Study 33416285 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Number of subjects: 20
Study 33416500 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (10 sessions over 2 weeks and 20 sessions over 4 weeks)
Number of subjects: 200
Study 33416500 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 200
Study 33416500 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 200
Study 33416509 — intervention group
Group type: EXPERIMENTAL
Intervention: e-transfer tool
Number of subjects: 4
Study 33416509 — intervention group
Group type: COMPARATOR
Intervention: dictation only
Number of subjects: 4
Study 33416995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Symptom Assessment Scale (OSAS)
Number of subjects: 250
Study 33416995 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and performance status assessments
Number of subjects: 250
Study 33417036 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography in T2DM patients
Number of subjects: 36
Study 33417036 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC) (n=23)
Number of subjects: 36
Study 33417236 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental interventions (training, support, or both, with or without information)
Number of subjects: 2367
Study 33417474 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted preemptive tocilizumab (8-12 mg/kg)
Number of subjects: 70
Study 33417474 — intervention group
Group type: COMPARATOR
Intervention: Standard CRS management (LTBC)
Number of subjects: 70
Study 33417474 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted preemptive tocilizumab
Number of subjects: 70
Study 33417511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg once every 3 weeks) plus Ipilimumab (3 mg/kg once every 3 weeks) for four inductions, followed by Nivolumab (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.
Number of subjects: 52
Study 33417814 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment, details not available
Number of subjects: 0
Study 33417885 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural embodiment promoted by sensory feedback
Number of subjects: 0
Study 33417885 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33417919 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 1834
Study 33417919 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping
Number of subjects: 1834
Study 33418143 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech Therapy App (STAPP)
Number of subjects: 25
Study 33419080 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Through Play Plus Dads (LTP+ Dads) intervention, 10 sessions over three months.
Number of subjects: 18
Study 33419423 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with overt CS (newly diagnosed and recurrent)
Number of subjects: 180
Study 33419423 — intervention group
Group type: COMPARATOR
Intervention: Matched controls without CS
Number of subjects: 180
Study 33419448 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron folic acid (IFA) or long-lasting insecticide-treated bednets during ANC visit
Number of subjects: 1736
Study 33419448 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-pocket costs (OPC)
Number of subjects: 1736
Study 33419448 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent attending ANC
Number of subjects: 1736
Study 33419448 — intervention group
Group type: EXPERIMENTAL
Intervention: ANC attendance score
Number of subjects: 1736
Study 33419900 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Number of subjects: 1370
Study 33419900 — intervention group
Group type: COMPARATOR
Intervention: New ACLF diagnostic criteria
Number of subjects: 1370
Study 33419900 — intervention group
Group type: EXPERIMENTAL
Intervention: Future proteomic and metabolic omics analyses
Number of subjects: 1370
Study 33419913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor function assessment including hop performance, muscle strength, muscle activation, hip and ankle range of motion, and postural orientation.
Number of subjects: 200
Study 33419913 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D kinematics and joint position sense evaluation (for Umeå cohort).
Number of subjects: 200
Study 33420229 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus daily orally at 10 mg for 12 weeks
Number of subjects: 24
Study 33420629 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 71
Study 33420642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluzoparib (100 mg, p.o.) after meal consumption on day-1
Number of subjects: 16
Study 33420642 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg (p.o.) under fasting condition from day-5 to day-9
Number of subjects: 16
Study 33420642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluzoparib (100 mg, p.o.) after meal consumption on day-9
Number of subjects: 16
Study 33420678 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Care mobile application
Number of subjects: 36
Study 33420682 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of antithrombotic drugs used (0 to 8, interquartile range = 3-4)
Number of subjects: 10568
Study 33420804 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33420912 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning framework
Number of subjects: 201
Study 33420913 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33421071 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception cannabis use
Number of subjects: 1228
Study 33421178 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 30 mg and Carfilzomib 20/56 mg/m²
Number of subjects: 0
Study 33421757 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional transversus abdominis activation
Number of subjects: 44
Study 33421757 — intervention group
Group type: COMPARATOR
Intervention: Control (no transversus abdominis activation)
Number of subjects: 44
Study 33422025 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment strategies for tibial shaft fractures (TSFs) including various surgical techniques and implant materials, with no specific dosage or duration mentioned.
Number of subjects: 1000
Study 33422025 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic perioperative antibiotic prophylaxis, local antimicrobials, and timing of soft-tissue coverage.
Number of subjects: 1000
Study 33422084 — intervention group
Group type: EXPERIMENTAL
Intervention: R3™ Acetabular System with BIOLOX® Delta ceramic femoral head
Number of subjects: 175
Study 33422139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) at a single dose of 1 × 10
Number of subjects: 14
Study 33422139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs)
Number of subjects: 14
Study 33422153 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote-only communication with healthcare providers
Number of subjects: 88
Study 33422398 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 128
Study 33423113 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 242
Study 33423806 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed serous and endometrioid (SER-EM-M)
Number of subjects: 934
Study 33423806 — intervention group
Group type: COMPARATOR
Intervention: Pure serous (SER)
Number of subjects: 934
Study 33423806 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate serous vs. endometrioid (SER-EM-I)
Number of subjects: 934
Study 33424715 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological Intervention tailored for Patients with Cognitive Impairment (PIPCI), once a week for 10 weeks
Number of subjects: 120
Study 33424715 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training, once a week for 10 weeks
Number of subjects: 120
Study 33424715 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 120
Study 33424715 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological Intervention tailored for Patients with Cognitive Impairment (PIPCI)
Number of subjects: 120
Study 33424755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study 33424755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cryotherapy)
Number of subjects: 0
Study 33425328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified; data from Community-based Household Survey (2014-2017) used for analysis.
Number of subjects: 0
Study 33425330 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help groups (SHGs) members
Number of subjects: 62690
Study 33425329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) tool exposure
Number of subjects: 0
Study 33425329 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33425331 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-layering of self-help groups (SHGs) with health education modules
Number of subjects: 0
Study 33425331 — intervention group
Group type: COMPARATOR
Intervention: Standard self-help groups (SHGs) without health education modules
Number of subjects: 0
Study 33425333 — intervention group
Group type: EXPERIMENTAL
Intervention: AMANAT intervention (on-the-job, on-site nurse mentoring and training)
Number of subjects: 80
Study 33425334 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation and team-training intervention
Number of subjects: 668
Study 33425334 — intervention group
Group type: COMPARATOR
Intervention: Top one-third facilities (high simulation)
Number of subjects: 668
Study 33425334 — intervention group
Group type: COMPARATOR
Intervention: Maternal complication simulations
Number of subjects: 668
Study 33425334 — intervention group
Group type: COMPARATOR
Intervention: Middle one-third facilities (moderate simulation)
Number of subjects: 668
Study 33425335 — intervention group
Group type: EXPERIMENTAL
Intervention: Statewide maternal and child health program
Number of subjects: 10174
Study 33425385 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs and eye mask
Number of subjects: 2
Study 33425385 — intervention group
Group type: COMPARATOR
Intervention: Ocean sound
Number of subjects: 2
Study 33425441 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial perfusion of epirubicin, etoposide, and oxaliplatin combined with oral chemotherapy S-1 (SEEOX) for 3, 21-day courses
Number of subjects: 36
Study 33425441 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-arterial perfusion of epirubicin, etoposide, and oxaliplatin combined with oral chemotherapy S-1 (SEEOX)
Number of subjects: 36
Study 33425673 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of zoledronate
Number of subjects: 211
Study 33425673 — intervention group
Group type: COMPARATOR
Intervention: 6-monthly dosing of zoledronate
Number of subjects: 211
Study 33425801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl 0.2 mg in the fed state with a high-fat meal
Number of subjects: 0
Study 33425801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl 0.4 mg in the fed state with a high-fat meal
Number of subjects: 0
Study 33425801 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl 0.4 mg in the fasted state
Number of subjects: 0
Study 33425820 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic non-invasive auricular acupuncture during eye-exam
Number of subjects: 0
Study 33425820 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33425931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Health Promotion Program
Number of subjects: 0
Study 33425931 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33425946 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33426003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin added to Furosemide
Number of subjects: 0
Study 33426008 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethylamine N-Oxide
Number of subjects: 0
Study 33426066 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing technology with arthroscopic surgery
Number of subjects: 21
Study 33426066 — intervention group
Group type: COMPARATOR
Intervention: C-arm fluoroscopy with arthroscopic surgery
Number of subjects: 21
Study 33426802 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-20-30 training (high-intensity interval exercise training) for 10 weeks
Number of subjects: 12
Study 33426802 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetes counterparts (ND)
Number of subjects: 12
Study 33427211 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors with high matching score (≥50%)
Number of subjects: 40
Study 33427211 — intervention group
Group type: COMPARATOR
Intervention: CDK4/6 inhibitors with low matching score (<50%)
Number of subjects: 40